Does the management have a determination to continue to develop products or processes that will further increase total sales potentials when the growth potentials of currently attractive product lines have largely been exploited? - Philip Fisher If you've been following my blog , you'...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Market Perform rating at Oppenheimer. More news on: Arrowhead Pharmaceuticals, Inc., Exact Sciences Corporation, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) allowing the U.S. Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. To promote getting novel medicines to patients expeditiously, the act requires the FDA to...